US health regulators create a fast lane for new respiratory disease tests
What happened
US health regulators just created a new, faster approval process for diagnostic tests that can detect multiple respiratory diseases at once. This means new tests for diseases like flu, RSV, and future emerging pathogens can get to market more quickly.
Why it matters
For years, getting a new medical diagnostic test approved meant navigating a slow, complex process, especially for novel technologies. This new classification streamlines that path for a specific type of test, making it easier for companies to bring new tools to doctors and patients. It also sets a precedent for how regulators might handle future diagnostic innovations, particularly those designed to identify multiple threats simultaneously.
The signal
Watch for an increase in the number of new multiplex respiratory panels entering the market in the next 12-24 months, and whether their approval times are significantly shorter than previous diagnostic tests.